Valuation: Amgen Inc.

Market Cap 208B 182B 172B 156B 292B 20,006B 293B 2,056B 794B 10,171B 783B 766B 32,728B P/E 2026 *
24.4x
P/E 2027 * 21.9x
Enterprise Value 250B 218B 206B 187B 350B 23,987B 352B 2,465B 951B 12,195B 939B 918B 39,240B EV / Sales 2026 *
6.42x
EV / Sales 2027 * 6.07x
Free-Float
99.77%
Yield 2026 *
2.62%
Yield 2027 * 2.76%
1 day+0.92%
1 week+1.93%
Current month-10.58%
1 month-12.99%
3 months+12.53%
6 months+8.05%
Current year+14.61%
1 week 27.73
Extreme 27.73
28.52
1 month 27.73
Extreme 27.73
32.94
Current year 23.95
Extreme 23.95
32.94
1 year 23.95
Extreme 23.95
32.94
3 years 23.95
Extreme 23.95
32.94
5 years 23.95
Extreme 23.95
32.94
10 years 23.95
Extreme 23.95
32.94
Manager TitleAgeSince
Chief Executive Officer 63 2012-04-30
Director of Finance/CFO 62 2010-05-12
Chief Tech/Sci/R&D Officer 57 2023-05-31
Director TitleAgeSince
Chairman 63 2012-12-31
Director/Board Member 65 2011-12-31
Director/Board Member 71 2011-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%+1.93% - - 208B
+0.04%+3.34%+53.32%+100.52% 1,028B
-0.09%+1.66%+53.24%+66.45% 651B
-0.02%+2.66%+18.65%+71.97% 466B
-1.22%+3.66%+34.59%+38.81% 346B
-0.79%+2.73%+17.73%+25.11% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+45.91% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+98.11% 186B
Average +0.12%+3.26%+25.25%+45.35% 400.19B
Weighted average by Cap. +0.02%+3.09%+34.84%+61.60%

Financials

2026 *2027 *
Net sales 38.94B 33.95B 32.06B 29.11B 54.55B 3,736B 54.77B 384B 148B 1,900B 146B 143B 6,112B 40.23B 35.08B 33.13B 30.08B 56.36B 3,861B 56.6B 397B 153B 1,963B 151B 148B 6,315B
Net income 8.68B 7.57B 7.15B 6.49B 12.16B 833B 12.21B 85.59B 33.03B 423B 32.6B 31.88B 1,362B 9.34B 8.15B 7.69B 6.98B 13.09B 896B 13.14B 92.14B 35.55B 456B 35.09B 34.31B 1,466B
Net Debt 41.49B 36.18B 34.16B 31.02B 58.11B 3,981B 58.36B 409B 158B 2,024B 156B 152B 6,512B 35.82B 31.23B 29.49B 26.78B 50.17B 3,437B 50.38B 353B 136B 1,747B 135B 132B 5,622B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
26-09-18 $28.47 +0.92% 5,947
26-09-17 $28.21 +1.58% 600
26-09-16 $27.77 -0.75% 4,180
26-09-15 $27.98 -1.13% 2,069
26-09-14 $28.30 +1.32% 3,010
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
33
Last Close Price
385.65USD
Average target price
387.69USD
Spread / Average Target
+0.53%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!